NCT00346255View on ClinicalTrials.gov

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Multiple Myeloma
Interventions
DRUG

BB-10901

dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.

Trial Locations (8)

10011

St. Vincent's Comprehensive Cancer Center - Manhattan, New York

94143

UCSF, San Francisco

Unknown

Cedars-Sinai Outpatient Cancer Center, Los Angeles

Juan Domingo Peron 1500 - (B1629AHJ) Pilar, Buenos Aires

Gascon 450 - (C1181ACH), Buenos Aires

Av. Naciones Unidas 346. (X5016KEH)-Barrio Parque Velez Sarfield, Córdoba

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

14263-0001

Roswell Park Cancer Institute, Buffalo

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY